What question did this study set out to answer?

To assess the efficacy of anakinra for treating refractory ICANS in CAR T-cell therapy recipients.

December 8, 2025Blood

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

View Full Paper

Ask AI

Bookmark

Authors

Multicenter analysis shows anakinra improves ICANS symptoms in CAR T-cell therapy recipients, indicating effective steroid management.

To assess the efficacy of anakinra for treating refractory ICANS in CAR T-cell therapy recipients.
Multicenter cohort analysis of 124 adults with hematologic malignancies receiving CAR T-cell therapy.
Anakinra administered for steroid-refractory ICANS, with analyses of patient outcomes and factors influencing treatment efficacy.
Cumulative incidence estimates computed for time to ICANS resolution with death as a competing risk.
ICANS resolution occurred after a median of 10 days following anakinra initiation.
Ninety-four patients (89%) achieved complete or partial anti-tumor responses at day +28.
Higher daily dexamethasone doses correlated with shorter time to ICANS resolution.

Kungwankiattichai et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark